Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 added to first-line cART in treatment-naive HIV-1 infection
ACTRN12621000937819Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing BIT225 + cART with Placebo + cART (2 arms). Primary endpoints: Antiviral activity, Safety and tolerability and 1 more. Started Nov 2021; status: completed.
02
Drugs
BIT225
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12621000937819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000937819.